翰宇藥業(300199.SZ):超募資金投資項目結項 剩餘募集資金永久補充流動資金
格隆匯1月14日丨翰宇藥業(300199.SZ)公佈,根據《深圳證券交易所創業板股票上市規則》《深圳證券交易所創業板上市公司規範運作指引》等法律法規及規範性文件的規定,結合公司發展規劃及實際生產經營的需要,公司決定將超募資金投資項目“購買科信必成自主研發的21項口服緩控釋製劑品種的藥品項目”結項,並將剩餘超募資金3316.00萬元及其利息收入902.09萬元,合計4218.09萬元全部用於永久補充公司日常運營所需的流動資金。最終永久補充流動資金的利息金額以資金轉出當日銀行結息餘額為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.